Stock Report

Download full stock data and analysis for free Last Updated: 17-May-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Cidara Therapeutics Inc. (CDTX)

Stock Card factsheet share-fund-plan-icon

$221.38

$0.00 (0.00%)

As on 08-Jan-2026 09:30EDT

Market cap

info icon

$6,962 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

16.5

Div. Yield

info icon

0 %

Cidara Therapeutics (CDTX) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 221.38 High: 221.38

52 Week Range

Low: 15.22 High: 221.42

Liquidityliquidity Low

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -0.7 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    -1.6

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-14

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    31,446,306

10 Years Aggregate

CFO

$-339.13 Mln

EBITDA

$-420.07 Mln

Net Profit

$-416.09 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Cidara Therapeutics (CDTX)
0.2 0.5 116.7 719.9 545.5 148.6 30.4
BSE Sensex*
-11.1 -2.1 -8.9 -7.5 6.6 9.1 11.4
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 08-Jan-2026  |  *As on 15-May-2026  |  #As on 26-Oct-2023
Company
2025
2024
2023
2022
2021
2020
2019
Cidara Therapeutics (CDTX)
721.8 3,189.6 5.0 -40.5 -36.5 -47.9 63.4
S&P Small-Cap 600
4.0 7.0 13.9 -17.4 25.3 9.6 20.9
BSE Sensex
9.1 8.1 18.7 4.4 22.0 15.8 14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Peers

View Details
Company
 Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Cidara Therapeutics (CDTX)
221.4 6,961.6 0.0 -184.7 -- -65.5 -- 16.5
Mersana Therapeutics (MRSN)
29.1 145.4 33.2 -70.1 -202.9 -- -- 32.0

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Cidara Therapeutics (CDTX)

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the...  echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.  Read more

  • President, CEO & Executive Director

    Dr. Jeffrey L. Stein Ph.D.

  • President, CEO & Executive Director

    Dr. Jeffrey L. Stein Ph.D.

  • Headquarters

    San Diego, CA

  • Website

    https://www.cidara.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Cidara Therapeutics (CDTX)

The share price of Cidara Therapeutics Inc (CDTX) is $221.38 (NASDAQ) as of 08-Jan-2026 09:30 EDT. Cidara Therapeutics Inc (CDTX) has given a return of 545.5% in the last 3 years.

Since, TTM earnings of Cidara Therapeutics Inc (CDTX) is negative, P/E ratio is not available.
The P/B ratio of Cidara Therapeutics Inc (CDTX) is 16.48 times as on 08-Jan-2026, a 267 premium to its peers’ median range of 4.49 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2024
-1.54
1.60
2023
-0.16
-0.44
2022
-0.09
-0.19
2021
-0.09
0.19
2020
-0.06
0.41

The 52-week high and low of Cidara Therapeutics Inc (CDTX) are Rs 221.42 and Rs 15.22 as of 17-May-2026.

Cidara Therapeutics Inc (CDTX) has a market capitalisation of $ 6,962 Mln as on 08-Jan-2026. As per SEBI classification, it is a Small Cap company.

Before investing in Cidara Therapeutics Inc (CDTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.